Log In

Forgot Password?
Create New Account

Loading... please wait

2018 Annual Meeting | C136 - Multiple Sclerosis Therapy: Disease-modifying Treatment I

Wednesday 04/25/18
07:00 AM - 09:00 AM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Seminar
David E. Jones, MD, FAAN, , Scott D. Newsome, DO, FAAN
Participants should be familiar with the indications and risks associated with approved disease-modifying agents in multiple sclerosis, and be better able to identify the appropriate patient populations for the newer agents.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Advanced Practice Provider
Trainee, General Neurologist, Specialist Neurologist
Didactic, Interactive
Event Timeline
07:00 AM - 08:00 AM Speaker A Brave New World of MS Therapeutics
Scott D. Newsome, DO, FAAN
08:00 AM - 08:45 AM Speaker MS Treatment Paradigms, Risk Mitigation, and Sequencing Considerations
Gabriel Pardo, MD, FAAN
08:45 AM - 09:00 AM Q&A Questions and Answers
Faculty Disclosures
David E. Jones, MD, FAAN Dr. Jones has received personal compensation for serving as an employee of Genentech. Dr. Jones has stock in Roche.
Gabriel Pardo, MD, FAAN Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche Genentech. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi Genzyme. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Pardo has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche Genentech. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Pardo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Horizon Therapeutics. Dr. Pardo has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals.
No disclosure on file
Scott D. Newsome, DO, FAAN Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from The Stiff Person Syndrome Research Foundation. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.